Blueprint Medicines Corporation (BPMC)
收市後：
| 前收市價 | 49.37 |
| 開市 | 49.35 |
| 買盤 | 48.28 x 800 |
| 賣出價 | 50.85 x 1200 |
| 今日波幅 | 48.60 - 50.19 |
| 52 週波幅 | 37.82 - 68.63 |
| 成交量 | |
| 平均成交量 | 626,369 |
| 市值 | 3.004B |
| Beta 值 (5 年，每月) | 0.74 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -9.01 |
| 業績公佈日 | 2023年10月30日 - 2023年11月03日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 74.59 |
InvestorPlace3 Biotech Stocks Using AI to Change Healthcare Forever
The past year provided a peek into the future of biotech and healthcare. Megafirms like Medtronic (NYSE:MDT) led the way, partnering with tech giants such as Nvidia (NASDAQ:NVDA), to develop AI-powered solutions to medical problems. While these mainstays take advantage of artificial intelligence and machine learning, they aren’t the only opportunities for savvy investors. A slew of quality biotech firms are flying under the radar, advancing by leaps and bounds toward changing healthcare forever.
InvestorPlace3 Small-Cap Drug Stocks to Watch as Their Clinical Trials End Soon
Major large cap pharmaceutical firms often dominate the headlines. However, small cap drug companies also contribute significantly to scientific advancements. Drug stocks with ongoing clinical trials usually experience significant stock movement based on trial results. So, it’s vital for investors to stay informed about these trials. The top drug stocks to watch usually have imminent successful trials. Next, understanding the science behind the drugs is crucial. Knowledge about the disease, the
BenzingaFDA Removes Partial Clinical Hold From Blueprint Medicines' Cancer Study
The FDA lifted the partial clinical hold on Blueprint Medicines Corporation's (NASDAQ: BPMC) Phase 1/2 VELA trial of BLU-222. In February, the agency placed a partial clinical hold on the VELA trial due to reported visual adverse events, consisting of transient, reversible episodes of light sensitivity and blurred vision, observed in a limited number of patients. Patients already enrolled in the trial have continued receiving the study drug. "With a focus on patient safety, we have worked dilige
